• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 69
  • 66
  • 42
  • 26
  • 17
  • 13
  • 9
  • 8
  • 6
  • 5
  • 4
  • 2
  • 2
  • 2
  • 2
  • Tagged with
  • 305
  • 48
  • 28
  • 27
  • 27
  • 24
  • 22
  • 20
  • 19
  • 17
  • 17
  • 15
  • 15
  • 15
  • 15
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
71

Fibroblast growth factor-23 and Klotho in bone/mineral and parathyroid disorders

Krajisnik, Tijana January 2009 (has links)
Fibroblast growth factor-23 (FGF23) is a novel, bone-produced hormone that regulates renal phosphate (Pi) reabsorption and calcitriol metabolism. Disorders of mineral and bone metabolism, such as autosomal dominant hypophosphatemic rickets (ADHR) and hyperostosis-hyperphosphatemia syndrome (HHS), witness the importance of well-balanced serum levels of FGF23. Patients with chronic kidney disease (CKD) are highly morbid due to Pi retention/hyperphosphatemia and calcitriol deficiency, which lead to elevated serum levels of parathyroid hormone (PTH) and secondary hyperparathyroidism (sHPT). As a response to hyperphosphatemia, CKD patients have also remarkably high serum FGF23 levels, which are associated with cardiovascular risk factors and increased mortality in CKD. The overall aim of this dissertation was to discern a possible role of FGF23 in parathyroid biology. Our in vitro experiments on isolated bovine parathyroid cells demonstrate that FGF23 directly and dose-dependently suppresses the PTH production and secretion, while increasing the expression of the 25-hydroxyvitamin D3-activating enzyme 1α-hydroxylase. We investigated possible expressional changes in the FGF23 receptor co-factor Klotho in hyperparathyroid disorders and found that Klotho expression is decreased or absent and inversely correlated to serum calcium (Ca) in adenomas of primary HPT (pHPT). In the hyperplastic parathyroid glands of sHPT, Klotho expression declines in parallel with the kidney function and correlates with the glomerular filtration rate. Moreover, Klotho expression is suppressed by Ca and FGF23, increased by calcitriol, but unaffected by Pi and PTH in vitro. Finally, we identified a novel missense mutation in the gene encoding GALNT3, which is normally involved in the post-translational glycosylation of FGF23, as the cause of aberrant FGF23 processing in a patient with HHS. In summary, we provide evidence for a novel bone/parathyroid axis in which FGF23 functions as a direct, negative regulator of the PTH production. High extracellular Ca is a major determinant of the Klotho expression in pHPT, whereas the Klotho levels in sHPT may be attributed to a combination of the high FGF23 and Ca, and low calcitriol levels associated with CKD. Hence, the decreased Klotho expression in sHPT could explain the concomitantly high FGF23 and PTH levels, as well as the failure of FGF23 to prevent or mitigate the development of sHPT in CKD.
72

Etude de l’implication de l’axe IL-23/Th17 dans deux modèles physiopathologiques humains : la réponse à Mycoplasma hominis et la sclérodermie systémique / Study of the IL-23/Th17 axis involvement in two physiopathological human models : response to Mycoplasma hominis and systemic sclerosis

Truchetet, Marie-Élise 29 November 2012 (has links)
La nature du lien qui unit les deux aspects du système immunitaire, que sont la défense de l’hôte contre les agressions extérieures et la genèse des maladies auto- immunes, n’a pas été élucidée. L’axe IL-23/Th17 joue un rôle dans les deux versants, ce qui le place en bonne position pour être un potentiel chaînon manquant. Objectif : connaître l’implication de cet axe dans un modèle infectieux, Mycoplasma hominis, et un modèle de maladie auto-immune, la sclérodermie systémique (ScS), dans lesquels il n’a pas encore été étudié. Les lipoprotéines membranaires de M. hominis sont capables d’induire une maturation des cellules dendritiques humaines. Elle s’accompagne d’une sécrétion d’IL-23 variable selon l’origine clinique des isolats, via TLR2, et d’une polarisation vers la voie Th17. Nous avons observé une augmentation de la fréquence des cellules Th17 et Th22 dans le sang périphérique des patients ScS, potentialisée par l’iloprost, via entre autres la production monocytaire d’IL-23. Dans la peau des patients ScS, il existe une augmentation des cellules produisant l’IL-17 inversement corrélé au score de fibrose cutanée. In vitro, l’IL-17 est capable d’inhiber partiellement l’expression d’α-SMA induite par le TGF-ß et d’induire la sécrétion de MMP1 par des fibroblastes dermiques humains. L’axe IL-23/IL-17 et les cellules Th17 jouent un rôle dans la défense contre M. hominis et dans la physiopathologie de la ScS. / Relationship between both aspects of the immune system, ie host defense against external aggression and genesis of autoimmune diseases, has not been elucidated. IL-23/Th17 axis plays a role in both sides, which puts him in a good position to be a potential missing link. Objective: To understand the implication of this axis in a model of infection, Mycoplasma hominis, and a model of autoimmune disease, systemic sclerosis (SSc), in which it has not yet been studied.
The membrane lipoproteins of M. hominis are capable of inducing human dendritic cell maturation. It occurs along with an IL-23 secretion changing with the clinical origin of isolates, via TLR2, and a T cell polarization towards Th17. Then we observed an increase in the Th17 and Th22 cell frequency in peripheral blood of SSc patients, further enhanced by iloprost via monocyte production of IL-23 among others. In the skin of SSc patients, we showed an increase in IL-17-producing cells with an inverse correlation to the skin fibrosis score. In vitro, IL-17 is able to partially inhibit the expression of α-SMA induced by TGF-ß and to induce the secretion of MMP1 in human dermal fibroblasts. The IL-23/IL-17 axis and Th17 cells play a role in defense against M. hominis and in the pathogenesis of SSc.
73

Avaliação do metabolismo proteico e mineral e do status pró-inflamatório e oxidativo de cães doentes renais crônicos alimentados com dieta de prescrição para pacientes nefropatas / Evaluation of protein and mineral metabolism and proinflammatory and oxidative status in dogs with chronic kidney disease fed with diet prescription for kidney disease patients

Halfen, Dóris Pereira 25 November 2016 (has links)
A doença renal crônica (DRC) é a afecção renal mais frequente em cães e caracteriza-se pela progressiva redução do número de néfrons funcionais. Com a evolução da doença, os cães podem apresentar um conjunto de manifestações clínicas denominada uremia. O suporte nutricional objetiva atenuar os efeitos do estado urêmico, retardar a progressão da doença e melhorar a qualidade de vida dos animais. O presente estudo objetivou avaliar os efeitos da dieta coadjuvante e manejo dietético no metabolismo de cálcio e fósforo [fósforo, cálcio total (CaT), cálcio iônico (Cai), paratormônio (PTH) e FGF-23 séricos], escore de condição corporal (ECC), escore de massa muscular (EMM), concentrações séricas de aminoácidos (AAs) e citocinas inflamatórias (CIT), bem como a capacidade antioxidante total (CAT) de cães com DRC alimentados com dieta coadjuvante. Foram selecionados 10 cães com DRC estádios 3 e 4 (IRIS, 2015) provenientes do atendimento do Hospital Veterinário da Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo. As variáveis PTH, FGF-23, AAs, CIT e CAT foram avaliadas no início do estudo (T0) e após 6 meses de manejo dietético (T6). As determinações séricas de ureia, creatinina, CaT, Cai e fósforo; ECC e EMM foram determinadas em T0 e a cada 30 dias, durante os 6 meses de estudo. Para a análise dos resultados, testes estatísticos paramétricos e não paramétricos foram empregados e valores de p&lt;0,05 foram considerados significativos. As concentrações séricas de ureia, fósforo, CaT, Cai, IL-6, IL-10, TNF-&#945;, CAT, PTH e FGF-23 não apresentaram diferença entre os momentos T0 e T6. A creatinina elevou-se em T6 (p=0,0022). Os AAs fenilalanina, triptofano e ornitina decresceram no tempo T6 (p=0,0273; p=0,0253; p=0,0443, respectivamente) e a hidroxiprolina aumentou em T6 (p=0,0073). As concentrações séricas de PTH apresentaram correlação com a creatinina e ureia (r=0,45, p&lt;0,05; r=0,67, p&lt;0,01; respectivamente). O Cai apresentou correlação negativa com a ureia (r=-0,59, p&lt;0,01) e o fósforo sérico apresentou correlação positiva com o FGF-23 (r=0,51; p&lt;0,05). A ureia e creatinina apresentaram correlação positiva (r=0,62; p&lt;0,01). De acordo com os resultados encontrados, conclui-se que a dieta e o manejo nutricional empregados foram eficazes no controle do hiperparatireoidismo secundário renal, estresse oxidativo, marcadores inflamatórios e na manutenção do escore de condição corporal, massa muscular e nutrição proteica dos cães avaliados. / Chronic kidney disease (CKD) is the most common kidney disease in dogs and characterized by progressive reduction in the number of functional nephrons. With the evolution of the disease the dogs may present a set of clinical manifestations denominated uremia. The efforts of nutritional support are to mitigate the effects of uremic state, slow the progression of the disease and improve the quality of life of the animals. The aim of this study was to evaluate the effects of prescription diet and dietary management on the metabolism of calcium and phosphorus [phosphorus, total calcium (CaT), ionized calcium (Cai), parathyroid hormone (PTH) and FGF-23 in the serum], body condition score (BCS), muscle mass score (MME), serum concentrations of amino acids (AAs) and inflammatory cytokines (CYT), as well as the total antioxidant capacity (TAC) of dogs with CKD fed with a coadjuvant diet. Were selected 10 dogs with CKD stage 3 and 4 (IRIS, 2015), from the Veterinary Hospital at School of Veterinary Medicine and Animal Science, University of São Paulo. The PTH, FGF-23, AAs, CYT and TAC variables were evaluated at baseline (T0) and after 6 months of dietary management (T6). The serum determinations of urea, creatinine, CaT, Cai and phosphorus; BCS and MMS were determined at T0 and every 30 days, for 6 months. For the analysis of the results, parametric and non-parametric statistical tests were used and values of p<0.05 were considered significant. Serum concentrations of urea, phosphorus, CaT, Cai, IL-6, IL-10, TNF-&#945;, CAT, PTH, FGF-23 did not differ between T0 and T6. Serum creatinine increased in T6 (p=0.0022). The AAs phenylalanine, tryptophan and ornithine decreased in T6 (p=0.0273; p=0.0253; p=0.0443, respectively) and hydroxyproline increased in T6 (p=0.0073). Serum PTH concentrations correlate positively with the concentrations of creatinine and urea (r=0.45, p&lt;0.05; r=0.67, p&lt;0.01; respectively). The Cai was negatively correlated with urea (r = -0.59, p&lt;0.01) and serum phosphorus was positively correlated with FGF-23 (r = 0.51; p&lt;0.05). The urea and creatinine were positively correlated (r=0.62; p&lt;0.01). It was concluded that diet and nutritional management were effective in the control of renal secondary hyperparathyroidism, oxidative stress, inflammatory markers and maintenance of body condition score, muscle mass and protein nutrition in the evaluated dogs.
74

Expressão de Foxp3, IL-17 e IL-23 na Leishmaniose Tegumentar Americana causada por Leishmania (Leishmania) amazonensis e Leishmania (Viannia) braziliensis / Expression of Foxp3, IL-17 and IL-23 in American cutaneous leishmaniasis due Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis

Menezes, Joyce Prieto Bezerra de 13 September 2013 (has links)
A leishmaniose tegumentar americana (LTA) apresenta um amplo espectro de manifestações clínicas e imunopatológicas resultante da interação entre as diferentes espécies de Leishmania e os mecanismos de resposta imune do hospedeiro. Leishmania (Viannia) braziliensis e Leishmania (Leishmania) amazonensis são as espécies de maior potencial patogênico para o homem e de importância médica no Brasil. As células TCD4, quando ativadas por antígenos via MHC II podem se diferenciar em linhagens de células efetoras como Th1, Th2, Th17 e células T reguladoras (Treg). IL-23 é indispensável para as funções efetoras e manutenção de células Th17. O objetivo deste trabalho foi avaliar a expressão de Foxp3, IL-17 e IL-23 em lesões cutâneas de pacientes com diferentes formas clínicas da LTA. Biópsias parafinadas de 44 pacientes foram submetidas à imunoistoquímica, sendo 6 casos de leishmaniose cutânea anérgica difusa (LCADIDRM-) e leishmaniose cutânea disseminada borderline (LCDBIDRM-), ambas causadas por L.(L) amazonensis e 16 casos de leishmaniose cutânea localizada (LCLIDRM+) também causada por L.(L.) amazonensis; 9 casos de LCLIDRM+, 2 casos de LCDBIDRM- e 5 casos de leishmaniose cutâneo-mucosa (LCMIDRM+), todos causados por L.(V.) braziliensis. A densidade de células Tregs Foxp3+ no espectro clínico da LTA mostrou um aumento progressivo partindo das formas centrais LCL causadas por L.(V.) braziliensis (170mm2) e L.(L) amazonensis (140mm2) para as formas polares, LCADIDRM- (289mm2) e LCDBIDRM- (183mm2) causada por L.(L) amazonensis, LCDBIDRM- (189mm2) e LCMIDRM+, causadas por L.(V.) braziliensis (158mm2). A comparação entre as densidades de células IL-17+ nas diferentes formas clínicas da LTA mostrou um perfil semelhante também com um aumento progressivo da expressão de IL-17 partindo das formas centrais LCLIDRM+ causadas por L.(V.) braziliensis (232mm2) e L.(L) amazonensis (197mm2) em direção as formas polares, LCADIDRM- (470mm2) e LCDBIDRM- (340mm2) causada por L.(L.) amazonensis, LCDBIDRM- (431mm2) e LCMIDRM+ (372mm2) causada por L.(V.) braziliensis. A densidade de células IL-23+ mostrou perfil similar ao de IL-17 como no espectro de doença causada por L. (V.) braziliensis ou L. (L.) amazonensis: LCADIDRM- (687mm2), LCDBIDRM- (518mm2) e LCLIDRM+ (348mm2) por L.(L.) amazonensis, LCLIDRM+ (457mm2), LCDBIDRM- (609mm2) e LCMIDRM+ (568mm2) L. (V.) braziliensis. Diante dos nossos achados, observa-se que as células Foxp3+, IL-17+ e IL-23+ desempenham um papel importante na imunopatogênese das diferentes formas clínicas da LTA causadas por L. (V.) braziliensis ou L. (L.) amazonensis, caracterizada por uma resposta imune polarizada de diferente expressão patológica / The American cutaneous leishmaniasis (ACL) presents a wide spectrum of clinical and immunopathological manifestations resulting from the interaction between the different species of Leishmania and the mechanisms of the host immune response. Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis are the species with the largest pathogenic potential for humans and medical importance in Brazil. The CD4+ T cells can be differentiated into effector cell lines as Th1, Th2, Th17 and regulatory T cells (Treg). IL-23 is essential for effector functions and maintenance of Th17 cells, that produces IL-17. The aim of this study was to evaluate the expression of Foxp3, IL-17 and IL-23 in cutaneous lesions of patients with different clinical forms of ACL. Paraffin embedded biopsies from 44 patients were submitted to immunohistochemistry, there were 6 cases of anergic diffuse cutaneous leishmaniasis (ADCLDTH-) and borderline disseminated cutaneous leishmaniasis (BDCLDTH-) both caused by L. (L.) amazonensis 16 cases of cutaneous leishmaniasis (LCLDTH+) caused by L. (L.) amazonensis, 9 cases of LCLDTH+, 2 cases of BDCLDTH- and 5 cases of mucocutaneous leishmaniasis (MCLDTH+) all caused by L. (V.) braziliensis. The density of Treg Foxp3+ cells in the clinical spectrum of ACL showed a progressive increase starting from the central forms LCLDTH+ caused by L. (V.) braziliensis (170mm2) and L. (L) amazonensis (140mm2) towards the polar forms ADCLDTH- (289mm2). The intermediate clinical forms BDCLDTH- (183mm2) caused by L. (L) amazonensis and BDCLDTH-(189mm2) by L. (V.) braziliensis as well as, MCLDTH+(158mm2) did not present any significant differences. The comparison between the densities of IL-17+ cells in different clinical forms of ACL showed progressive increasing starting from the central forms LCLDTH+ caused by L. (V.) braziliensis (232mm2) and L. (L) amazonensis (197mm2) towards the polar forms, ADCLDTH-(470mm2) and BDCLDTH-(340mm2) caused by L. (L.) amazonensis BDCLDTH- (431mm2) and MCLDTH+ (372mm2) caused by L. (V.) braziliensis. The density of IL-23+ cells showed a similar profile to that of IL-17 at the disease spectrum caused by L. (V.) braziliensis and L. (L.) amazonensis: ADCLDTH-(687mm2) BDCLDTH-(518mm2) and LCLDTH+ (348mm2) by L. (L.) amazonensis; LCLDTH+ (457mm2) LCDBDTH-(609mm2) and MCLDTH+ (568mm2) L. (V.) braziliensis. In view of our findings, we notice that the Foxp3+, IL-17+ and IL-23+ cells play an important role in the immunopathogenesis of different clinical forms of ACL caused by L. (V.) braziliensis and L. (L.) amazonensis, characterized by an immune polarized response with different pathological expression
75

Tumores indutores de osteomalácia: diagnóstico, caracterização tumoral e avaliação evolutiva em longo prazo de nove pacientes / Tumor-induced osteomalacia: diagnosis, tumor characterization, and clinical evaluation in nine patients over a long-term period

Ferraz, Marcela Paula 14 April 2016 (has links)
INTRODUÇÃO: Tumores indutores de osteomalácia (TIOs) são raros, geralmente apresentam origem mesenquimal, têm produção excessiva de fosfatoninas sendo a mais comum o FGF23 (Fibroblast Growth Factor 23) que, em níveis elevados, provoca osteomalácia hipofosfatêmica. A cura dos TIOs envolve a remoção completa do tumor, o que torna essencial sua localização. OBJETIVOS: (1) caracterizar nove pacientes com TIO ao diagnóstico e avaliá-los evolutivamente em longo prazo; (2) avaliar a eficácia da cintilografia com Octreotida (Octreoscan®) e a da cintilografia de corpo inteiro com Mibi (MIBI) na detecção dos TIOs. MÉTODOS: O acompanhamento dos pacientes consistiu na avaliação clínica, na avaliação laboratorial com ênfase no metabolismo ósseo e na realização de exames de imagem para caracterização das deformidades esqueléticas. Para a localização dos TIOs, os pacientes foram submetidos a exames de Octreoscan®, MIBI, ressonância magnética (RM) e tomografia computadorizada (TC). RESULTADOS: O período de observação dos pacientes variou de dois a 25 anos. Ao diagnóstico, todos exibiam fraqueza muscular, dores ósseas e fraturas de fragilidade. Em relação à avaliação laboratorial, apresentavam: hipofosfatemia com taxa de reabsorção tubular de fosfato reduzida, fosfatase alcalina aumentada e níveis elevados de FGF23. O Octreoscan® permitiu a identificação dos TIOs nos nove pacientes e o MIBI possibilitou a localização dos TIOs em seis pacientes, sendo que ambos os exames foram concordantes entre si e com os exames topográficos (RM ou TC). Os achados histopatológicos das lesões dos nove pacientes confirmaram tratar-se de oito tumores mesenquimais fosfatúricos (PMTs) benignos e um PMT maligno. Após a primeira intervenção cirúrgica para a remoção dos TIOs, quatro pacientes encontram-se em remissão da doença e cinco evoluíram com persistência tumoral. Dos cinco, quatro foram reoperados e um aguarda nova cirurgia. Dos que foram reoperados, um paciente se mantém em remissão da doença, um foi a óbito por complicações clínicas, uma teve doença metastática e o último apresentou recidiva tumoral três anos após a segunda cirurgia. Deformidades ósseas graves foram observadas nos pacientes cujo diagnóstico e/ou tratamento clínico foram tardios. O tratamento da osteomalácia foi iniciado com fosfato e perdurou até a ressecção tumoral, tendo sido reintroduzido nos casos de persistência/recidiva tumoral. Quatro pacientes que fizerem uso regular desse medicamento por mais de seis anos evoluíram com hiperparatireoidismo terciário (HPT). CONCLUSÕES: O estudo revelou que tanto o Octreoscan® como o MIBI foram capazes de localizar os TIOs. Por isso, incentivamos a realização do MIBI nos locais onde o Octreoscan® não for disponível. Uma equipe experiente é indispensável para o sucesso cirúrgico visto que os tumores, embora benignos, costumam ser infiltrativos. Recomendamos o seguimento por tempo indeterminado em função do risco de recidiva tumoral. Assim como o FGF23, consideramos o fósforo um excelente marcador de remissão, persistência e recidiva dos TIOs. O diagnóstico e o tratamento precoce são fundamentais para a melhora dos sintomas podendo minimizar as deformidades esqueléticas e as sequelas ósseas. O uso prolongado do fosfato no tratamento da osteomalácia hipofosfatêmica foi associado ao desenvolvimento do HPT / BACKGROUND: Tumor-induced osteomalacia (TIO) is rare. The tumor usually has mesenchymal origin and produces excessive phosphatonins, most commonly FGF23 (Fibroblast Growth Factor 23), which at high levels causes hyphophostatemic osteomalacia. The cure for TIO is achieved through complete removal of the tumor. It is therefore essential identify its location. OBJECTIVES: (1) to characterize nine patients with TIO at diagnosis and to evaluate their follow-up over a long-term period; (2) to evaluate the efficacy of whole-body scintigraphy 111In-octreotide (Octreoscan®) and 99mTc-sestamibi (MIBI) in TIO detection. METHODS: Evaluations consisted of clinical and laboratory testing of bone metabolism and imaging to characterize skeletal deformities. To locate TIO, patients underwent Octreoscan®, MIBI, magnetic resonance (MRI), and computed tomography (TC). RESULTS: Patients were followed-up from two to 25 years. At diagnosis, all patients presented with muscle weakness, bone pain and fragility fractures. Laboratorial evaluation revealed hypophosphatemia with reduced tubular reabsorption of phosphate, increased alkaline phosphatase, and high levels of FGF23. TIO was identified in nine patients through Octreoscan® and in six patients through MIBI. Results of both types of scintigraphies matched one another as well with topographic examination (MR or CT). Histopathological findings of the lesions in the nine patients confirmed the existence of eight benign phosphaturic mesenchymal tumors (PMTs) and one malign PMT. After the first surgery for tumor resection, four patients were in remission, whereas five revealed tumoral persistence. Four of the latter five were re-operated, and one is still waiting for another surgery. Of those four patients, one became in remission, one died of clinical complications, one disclosed metastatic disease, and the last one had tumoral recurrence three years after the second surgery. Severe bone deformations were observed in patients whose diagnosis and/or clinical treatment were delayed. Osteomalacia treatment was initiated with oral phosphate, which continued until tumor resection. In case of tumor persistence or recurrence, oral phosphate was reintroduced. Four patients treated with this medication regularly for six years or more developed tertiary hyperparathyroidism (HPT). CONCLUSIONS: The present study revealed that Octreoscan® and MIBI were able to locating TIO. Therefore, we suggest that MIBI should be encouraged in places where Octreoscan® is not available. An expert team of surgeons is essential to the success of TIO\'s treatment, because of their infiltrative, albeit benign nature. Long-term follow-up is important due to the risk of tumor recurrence. Along with FGF23, phosphorous was considered an excellent hallmarker of TIO remission, persistence and recurrence. Early diagnosis and treatment are essential to improve symptoms and minimize skeletal deformities and skeletal disabilities. Long-term treatment of osteomalacia with oral phosphate was associated with the development of HPT
76

Avaliação do metabolismo mineral do doador de rim em vida / Evaluation of mineral metabolism in living kidney donor

Ferreira, Gustavo Fernandes 22 September 2014 (has links)
Introdução: Doador de rim em vida é uma importante fonte de órgão para os pacientes portadores de doença renal crônica (DRC). Os doadores experimentam uma redução abrupta da taxa de filtração glomerular (TFG) e adaptações ao metabolismo mineral demandam estudos nesta população. Nós avaliamos prospectivamente esta adaptação em doadores de rim em vida. Métodos: Entre janeiro de 2010 a agosto de 2011, no hospital das Clínicas de São Paulo e na Universidade de Miami, realizamos a avaliação prospectiva do metabolismo mineral e da função renal por 1 ano em 74 doadores de rim em vida. Medimos a taxa de filtração glomerular (TFG), fósforo (Pi), cálcio (Ca), paratohormônio (PTH), fibroblast Growth Factor 23 (FGF23) e a fração de excreção do fósforo (FePO4) no pré-operatório e nos dias 1, 2, 14, 180 e 360 do pós-operatório. Resultados: Observamos uma redução, aproximadamente, de 40% da TFG nos dois primeiros dias após a cirurgia. No décimo quarto dia após a nefrectomia, observamos o início da recuperação da TFG, chegando ao máximo da recuperação com 1 ano, quando se atingiu 68,6% da função renal se comparado com o dia anterior a doação (75,3 ml/min/1,73m2, p < 0,001). O cálcio sérico apresentou seu nadir no dia 1 (7,99 mg/dL; p < 0,01) e o Pi sérico atingiu seu nadir no dia 2 (2,61 mg/dL; p < 0,01). Já no dia 14, os valores de Ca e Pi retornaram aos valores basais tendo o fósforo evoluído novamente com valores inferiores ao basal no último dia de seguimento (3,36mg/dL; p < 0,001). FGF23 e PTH apresentaram elevação no D1 (111,0144,6 percentil 25-75: 16-63 RU/ml 64,9 30,3pg/mL; p < 0,01). Os valores de FGF23 se mantiveram elevados até o final do estudo enquanto que o PTH retornou aos valores de base no segundo dia e, a partir de então, manteve sem diferença do valores basais até o último dia de estudo. FePO4 elevou de 11,45,2% para 15,28,1% entre o pré-operatório e D365 (p < 0,01). Conclusão: A nefrectomia para doação de rim em 74 pacientes saudáveis elevou os valores de FGF23 durante todo o estudo juntamente com a FePO4. O fósforo, cálcio e PTH séricos apresentaram queda nos seus valores na primeira semana após a nefrectomia, e, com duas semanas após a cirurgia, retornaram aos valores basais mantendo-se estáveis até o final do estudo / Introduction: Living kidney donors (LKDs) experience an abrupt decline in glomerular filtration rate (GFR). Mineral metabolism adaptations in early CKD are still debated and not well studied in LKDs. We prospectively studied acute and long term mineral metabolism adaptation of LKDs. Materials and Methods: We measured renal function and mineral metabolites longitudinally for 1 year (days (D) 1, 2, 14, 180, & 365 post-operatively) in 74 healthy individuals who underwent kidney live donation. Results: eGFR (MDRD) decreased to 59% of its baseline on day 2 and started to increase at day 3, to its maximum at day 360 (75.3±15.6 ml/min/1.73m2, p < 0.01) wile FGF23 increased from 60.6 (25th-75th percentile 19-81 RU/mL) at baseline to 111.0±144.6 (p < 0.01) on day 1 and keep higher than baseline throwout the study. PTH rose maximally on day 1 (64.9 ± 30.3pg/ml) and returned to its base line on D2 and did not change after that. Total serum Calcium levels decreased from 9,40±0,48 mg/dL to a nadir of 7.99±0,51 mg/dL on day 1 (p < 0.001). Serum Phosphate levels reached their nadir on day 2 (2.61±0,52 mg/dL; p < 0.01). At D14 total calcium and phosphate levels had returned to baseline, but phosphate levels returned down on D360 (3.36±0,52 mg/dL; p < 0.001). Phosphate excretion fraction (FePO4) increased from base line (11.4±5.2%) up to 15.2±8.1% until D360 (p < 0.001). Conclusions: Abrupt reduction in eGFR induces physiological increases in FGF23 and PTH, and decreases in serum Ca and Pi in the first week. The changes in FGF23 and Pi urinary fractional excretion of Pi remain modestly yet significantly different from baseline throughout the first year after nephrectomy. Wile Ca, PTH and Pi serum levels are not significantly different from the baseline
77

Tumores indutores de osteomalácia: diagnóstico, caracterização tumoral e avaliação evolutiva em longo prazo de nove pacientes / Tumor-induced osteomalacia: diagnosis, tumor characterization, and clinical evaluation in nine patients over a long-term period

Marcela Paula Ferraz 14 April 2016 (has links)
INTRODUÇÃO: Tumores indutores de osteomalácia (TIOs) são raros, geralmente apresentam origem mesenquimal, têm produção excessiva de fosfatoninas sendo a mais comum o FGF23 (Fibroblast Growth Factor 23) que, em níveis elevados, provoca osteomalácia hipofosfatêmica. A cura dos TIOs envolve a remoção completa do tumor, o que torna essencial sua localização. OBJETIVOS: (1) caracterizar nove pacientes com TIO ao diagnóstico e avaliá-los evolutivamente em longo prazo; (2) avaliar a eficácia da cintilografia com Octreotida (Octreoscan®) e a da cintilografia de corpo inteiro com Mibi (MIBI) na detecção dos TIOs. MÉTODOS: O acompanhamento dos pacientes consistiu na avaliação clínica, na avaliação laboratorial com ênfase no metabolismo ósseo e na realização de exames de imagem para caracterização das deformidades esqueléticas. Para a localização dos TIOs, os pacientes foram submetidos a exames de Octreoscan®, MIBI, ressonância magnética (RM) e tomografia computadorizada (TC). RESULTADOS: O período de observação dos pacientes variou de dois a 25 anos. Ao diagnóstico, todos exibiam fraqueza muscular, dores ósseas e fraturas de fragilidade. Em relação à avaliação laboratorial, apresentavam: hipofosfatemia com taxa de reabsorção tubular de fosfato reduzida, fosfatase alcalina aumentada e níveis elevados de FGF23. O Octreoscan® permitiu a identificação dos TIOs nos nove pacientes e o MIBI possibilitou a localização dos TIOs em seis pacientes, sendo que ambos os exames foram concordantes entre si e com os exames topográficos (RM ou TC). Os achados histopatológicos das lesões dos nove pacientes confirmaram tratar-se de oito tumores mesenquimais fosfatúricos (PMTs) benignos e um PMT maligno. Após a primeira intervenção cirúrgica para a remoção dos TIOs, quatro pacientes encontram-se em remissão da doença e cinco evoluíram com persistência tumoral. Dos cinco, quatro foram reoperados e um aguarda nova cirurgia. Dos que foram reoperados, um paciente se mantém em remissão da doença, um foi a óbito por complicações clínicas, uma teve doença metastática e o último apresentou recidiva tumoral três anos após a segunda cirurgia. Deformidades ósseas graves foram observadas nos pacientes cujo diagnóstico e/ou tratamento clínico foram tardios. O tratamento da osteomalácia foi iniciado com fosfato e perdurou até a ressecção tumoral, tendo sido reintroduzido nos casos de persistência/recidiva tumoral. Quatro pacientes que fizerem uso regular desse medicamento por mais de seis anos evoluíram com hiperparatireoidismo terciário (HPT). CONCLUSÕES: O estudo revelou que tanto o Octreoscan® como o MIBI foram capazes de localizar os TIOs. Por isso, incentivamos a realização do MIBI nos locais onde o Octreoscan® não for disponível. Uma equipe experiente é indispensável para o sucesso cirúrgico visto que os tumores, embora benignos, costumam ser infiltrativos. Recomendamos o seguimento por tempo indeterminado em função do risco de recidiva tumoral. Assim como o FGF23, consideramos o fósforo um excelente marcador de remissão, persistência e recidiva dos TIOs. O diagnóstico e o tratamento precoce são fundamentais para a melhora dos sintomas podendo minimizar as deformidades esqueléticas e as sequelas ósseas. O uso prolongado do fosfato no tratamento da osteomalácia hipofosfatêmica foi associado ao desenvolvimento do HPT / BACKGROUND: Tumor-induced osteomalacia (TIO) is rare. The tumor usually has mesenchymal origin and produces excessive phosphatonins, most commonly FGF23 (Fibroblast Growth Factor 23), which at high levels causes hyphophostatemic osteomalacia. The cure for TIO is achieved through complete removal of the tumor. It is therefore essential identify its location. OBJECTIVES: (1) to characterize nine patients with TIO at diagnosis and to evaluate their follow-up over a long-term period; (2) to evaluate the efficacy of whole-body scintigraphy 111In-octreotide (Octreoscan®) and 99mTc-sestamibi (MIBI) in TIO detection. METHODS: Evaluations consisted of clinical and laboratory testing of bone metabolism and imaging to characterize skeletal deformities. To locate TIO, patients underwent Octreoscan®, MIBI, magnetic resonance (MRI), and computed tomography (TC). RESULTS: Patients were followed-up from two to 25 years. At diagnosis, all patients presented with muscle weakness, bone pain and fragility fractures. Laboratorial evaluation revealed hypophosphatemia with reduced tubular reabsorption of phosphate, increased alkaline phosphatase, and high levels of FGF23. TIO was identified in nine patients through Octreoscan® and in six patients through MIBI. Results of both types of scintigraphies matched one another as well with topographic examination (MR or CT). Histopathological findings of the lesions in the nine patients confirmed the existence of eight benign phosphaturic mesenchymal tumors (PMTs) and one malign PMT. After the first surgery for tumor resection, four patients were in remission, whereas five revealed tumoral persistence. Four of the latter five were re-operated, and one is still waiting for another surgery. Of those four patients, one became in remission, one died of clinical complications, one disclosed metastatic disease, and the last one had tumoral recurrence three years after the second surgery. Severe bone deformations were observed in patients whose diagnosis and/or clinical treatment were delayed. Osteomalacia treatment was initiated with oral phosphate, which continued until tumor resection. In case of tumor persistence or recurrence, oral phosphate was reintroduced. Four patients treated with this medication regularly for six years or more developed tertiary hyperparathyroidism (HPT). CONCLUSIONS: The present study revealed that Octreoscan® and MIBI were able to locating TIO. Therefore, we suggest that MIBI should be encouraged in places where Octreoscan® is not available. An expert team of surgeons is essential to the success of TIO\'s treatment, because of their infiltrative, albeit benign nature. Long-term follow-up is important due to the risk of tumor recurrence. Along with FGF23, phosphorous was considered an excellent hallmarker of TIO remission, persistence and recurrence. Early diagnosis and treatment are essential to improve symptoms and minimize skeletal deformities and skeletal disabilities. Long-term treatment of osteomalacia with oral phosphate was associated with the development of HPT
78

Régulation de l’excitabilité musculaire par le canal potassique EGL-23 et la voie de signalisation LIN-12/Notch chez le nématode C. elegans / Regulation of muscle excitability by the potassium channel EGL-23 and the LIN-12/Notch pathway in the nematode Caenorhabditis elegans

El Mouridi, Sonia 18 October 2018 (has links)
Les canaux potassiques à deux domaines pore (K2P) sont des régulateurs principaux de l’excitabilité cellulaire car ils jouent un rôle central dans l’établissement et le maintien du potentiel de repos des cellules animales. Malgré leur rôle fondamental, peu d’informations sont connues sur les processus cellulaires qui contrôlent la fonction des canaux K2P in vivo. En particulier, nous ne connaissons que quelques facteurs qui contrôlent directement le nombre, l’activité et la localisation des K2P à la surface des cellules.Durant ma thèse, j’ai utilisé des stratégies d’ingénierie du génome que j’ai associé à des approches génétiques afin de caractériser le canal potassique EGL-23. Pour cela, j’ai réalisé un crible suppresseur du phénotype de défaut de ponte du mutant egl-23(n601) et un crible visuel sur le rapporteur fluorescent traductionnel egl-23::TagRFP-T. Grâce au reséquençagecomplet du génome, j’ai pu cloner 4 gènes impliqués dans la régulation du canal EGL-23. / Two-pore domain potassium channels (K2P) are major regulators of cell excitability, playing a central role in the establishment and maintenance of the resting potential of animal cells. Despite their fundamental role, little is known about the cellular processes that control K2P channels function in vivo. In particular, we know only few factors that directly control thenumber, activity, and localization of K2P on the cell surface.During my thesis, I used state-of-the art genome engineering technologies combined with genetic approaches to characterize the C. elegans potassium channel EGL-23. For this, I realized a phenotypic suppressor screen of the egg-laying defective mutant egl-23(n601) and a visual screen on an egl-23 translational fluorescent reporter. Using whole genome sequencing, I was able to clone for new genes involved in EGL-23 regulation
79

Etude des réponses inflammatoires de la peau entraînées par des défauts de la barrière épidermique chez la souris / Dissecting cytokine networks in the inflammatory responses in epidermal barrier-defective skin

Li, Jiagui 30 September 2014 (has links)
Le mécanisme qui sous-tend la réponse inflammatoire en cas de défaut de la barrière épidermique reste à élucider. Dans cette étude, nous montrons qu’en cas de rupture de la barrière formée par le stractum corneum épidermal, une réponse inflammatoire mixte de type 17 et 2 est induite. Nous décrivons ici une régulation réciproque entre les axes cytokiniques IL-23/IL-17/IL-22 et TSLP/IL-4 qui conditionne l’apparition du phénotype inflammatoire au niveau cutané. Par ailleurs, nous démontrons également que la flore bactérienne présente à la surface de la peau est engagée dans l’induction de l’IL-23 et de la réponse de type 17 alors que le PAR2 stimule, quant à lui, l’expression de TSLP et à la réponse de type 2. Nos résultats montrent donc la complexité et l’hétérogénéité des réponses inflammatoires en conditions de rupture de la barrière cutanée et ont des implications au niveau des thérapies pour les maladies inflammatoires de la peau. / Dysfunction of the epidermal barrier has been recognized as a critical factor in the development of skin inflammation; yet, the mechanism underlying the inflammatory responses triggered by epidermal defects remains still elusive. Here, by employing mice with corneodesmosin (CDSN) gene ablated in keratinocytes, we show that upon the breakdown of the epidermal barrier, type 17 and type 2 inflammatory responses are co-induced in the skin. Furthermore, we delineate a counter-regulation between IL-23/IL-17/IL-22 and TSLP/IL-4 cytokine axes, which shapes the outcome of the inflammatory phenotype in skin. Moreover, we show that the bacteria skin flora are engaged in the induction of IL-23 and the type 17 response, whereas the protease activation receptor PAR2 mediates TSLP expression and the type 2 response. Our results shed light on the complexity and heterogeneity of inflammatory responses in barrier-defective skin, and have implications for treating skin inflammatory diseases.
80

An?lise da resposta Th17 em l?quen plano oral

Monteiro, Barbara Vanessa de Brito 24 February 2012 (has links)
Made available in DSpace on 2014-12-17T15:32:21Z (GMT). No. of bitstreams: 1 BarbaraVBM_DISSERT.pdf: 1563576 bytes, checksum: c536e73cdfce0251b3446e74e0f9cc69 (MD5) Previous issue date: 2012-02-24 / Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico / Th17 cells have been strongly associated with the pathogenesis of several autoimmune and inflammatory diseases. IL-17 and IL-23 are important cytokines associated with this lineage. The aim of this study was to analyze, through immunohistochemical methods, the immunoexpression of IL-17 and IL-23 in the inflammatory infiltrate of oral lichen planus (OLP) lesion compared to that of inflammatory fibrous hyperplasia (IFH) and between clinical forms reticular and erosive of OLP. The sample included 41 cases of OLP, of which 23 were reticular and 18 erosive and 10 cases of IFH. The results were subjected to nonparametric statistical tests with a 5% significance level. In OLP lesions histomorphological analysis, the most common findings were: hyperparakeratinization, specimens with atrophic epithelium in erosive clinical form (p = 0.011), epithelial projections in most of reticular type of lesions, in addition Civatte bodies were identified in most samples of both clinical forms. For immunohistochemistry analysis, five fields with strong immunoreactivity for IL-17 and IL-23 were photomicrographed at 400x magnification, images were transferred to a computer where with ImageJ software?, lymphocytes that exhibited cytoplasmic immunostaining for these cytokines were counted. A mean was established after for each case. There was no statistically significant difference in the number of imunopositive lymphocytes for IL-17 and IL-23 among the group of OLP and IFH group, however a larger amount of lymphocytes imunopositive for IL-17 was found in the LPO group (p = 0.079) and significantly higher amounts of those lymphocytes were found in the erosive OLP when compared to the group of reticular OLP and IFH (p = 0.019). Furthermore, a marker epithelial immunopositivity for IL-17 was observed in OLP group. Although the results of this study do not permit the forceful assertion about the participation of Th17 lineage in OLP lesions, the findings of immunopositive lymphocytes counting for IL-17 and IL-23, which are potent proinflammatory cytokines, together with the the marked epithelial immunopositivity found for IL-17 in this study, suggest a possible role of this lineage in the pathogenesis of this disorder / As c?lulas Th17 t?m sido fortemente associadas com a patogenia de diversas doen?as autoimunes e inflamat?rias. A IL-17 e a IL-23 s?o importantes citocinas associadas com esta linhagem. O objetivo do presente trabalho foi analisar, atrav?s de m?todos imunohistoqu?micos, a imunoexpress?o da IL-17 e da IL-23 no infiltrado inflamat?rio das les?es de l?quen plano oral (LPO) comparando ao da hiperplasia fibrosa inflamat?ria (HFI) e entre as formas cl?nicas reticular e erosiva do LPO com o intuito de esclarecer se a linhagem Th17 participa da patog?nese do LPO. Na amostra foram inclu?dos 41 casos de LPO, dos quais 23 eram reticulares e 18 erosivos, al?m de 10 casos de HFI. Os resultados foram submetidos a testes estat?sticos n?o param?tricos com n?vel de signific?ncia de 5%. Na an?lise histomorfol?gica das les?es de LPO, observou-se predom?nio de: les?es hiperparaceratinizadas, esp?cimes com epit?lio atr?fico na forma cl?nica erosiva (p=0,011), proje??es epiteliais nas les?es do tipo reticular, al?m de corpos de Civatte identificados na maior parte da amostra de ambas as formas cl?nicas. Para o estudo imuno-histoqu?mico, cinco campos com forte imunorreatividade para a IL-17 e para a IL-23 foram fotomicrografados sob o aumento de 400x, as fotos foram transferidas para um computador onde com o aux?lio do software ImageJ?, realizou-se a contagem dos linf?citos que exibiram imunomarca??o citoplasm?tica para estas citocinas. Posteriormente, foi estabelecida uma m?dia para cada caso. N?o foram observadas diferen?as estatisticamente significativas na quantidade de linf?citos imunopositivos para a IL-17 e para a IL-23 entre o grupo do LPO e da HFI, no entanto uma maior quantidade desses linf?citos para a IL-17 foi encontrada no grupo do LPO (p=0,079) e uma quantidade significativamente maior de linf?citos imunopositivos para a IL- 23 foi encontrada entre o grupo do LPO erosivo e da HFI (p=0,019). Al?m disto, foi observada uma marcante imunopositividade epitelial para a IL-17 no grupo do LPO. Ainda que os resultados do presente estudo n?o permitam a afirma??o contundente da participa??o da linhagem Th17 nas les?es de LPO, os achados da contagem dos linf?citos imunopositivos para a IL-17 e para a IL-23, que s?o potentes citocinas pr?-inflamat?rias, somados ? marcante imunopositividade epitelial encontrada para a IL-17 neste estudo, sugerem uma poss?vel participa??o desta linhagem na patog?nese desta desordem

Page generated in 0.0343 seconds